Search our Database of Scientific Publications and Authors

I’m looking for a

    113235 results match your criteria Malignant Melanoma

    1 OF 2265

    Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
    Cancer Treat Rev 2017 May 18;57:36-49. Epub 2017 May 18.
    Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Germany. Electronic address:
    Background: Combined immune checkpoint blockade (ICB) provides unprecedented efficacy gains in numerous cancer indications, with PD-1 inhibitor nivolumab plus CTLA-4 inhibitor ipilimumab in advanced melanoma as first-ever approved therapies for combined ICB. However, gains in efficacy must be balanced against a higher frequency and severity of adverse drug reactions (ADR). Because delays in diagnosis and management might result in symptom worsening and further complications, clinicians shall be well trained to identify ADR promptly and monitor patients adequately. Read More

    Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case.
    Clin J Gastroenterol 2017 May 26. Epub 2017 May 26.
    Department of Surgery, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto, 390-8621, Japan.
    Primary malignant melanoma of the esophagus (PMME) is a rare neoplasm. We observed a case of PMME that had occurred at an irradiated site in the thoracic esophagus. The patient was a 74-year-old man who had received definitive chemoradiotherapy for esophageal squamous cell carcinoma at the age of 68, and had completely recovered. Read More

    Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma.
    Ophthalmology 2017 May 23. Epub 2017 May 23.
    Retina Consultants of Houston, Houston, Texas; Blanton Eye Institute at Houston Methodist Hospital, Houston, Texas.
    Purpose: Gene expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes. It is unknown if a greater tumor regression response after iodine 125 (I(125)) brachytherapy correlates with class 2 GEP status. The purpose of this study was to determine whether there is a significant relationship between the rate of UM height regression and GEP classification testing after I(125) plaque brachytherapy. Read More

    Autoantibodies in Melanoma-Associated Retinopathy Recognize an Epitope Conserved Between TRPM1 and TRPM3.
    Invest Ophthalmol Vis Sci 2017 May;58(5):3732-3738
    Department of Physiology and Pharmacology, Oregon Health & Science University, Portland, Oregon, United States.
    Purpose: Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome associated with malignant melanoma and the presence of anti-retinal autoantibodies, including autoantibodies against transient receptor potential melanopsin 1 (TRPM1), a cation channel expressed by both melanocytes and retinal bipolar cells. The goal of this study was to further map the antigenic epitope.

    Methods: Patient sera were tested by immunofluorescence and Western blotting on HEK293 cells transfected with enhanced green fluorescent protein (EGFP)-TRPM1 fusion constructs and mouse retina sections. Read More

    Expression of Ki-67 and Estrogen Receptor Beta in Primary Cutaneous Melanoma as a Potential Indicator of Regional Lymph Node Positivity.
    Appl Immunohistochem Mol Morphol 2017 May 25. Epub 2017 May 25.
    *Department of Pathology, Clinical Center of the University of Sarajevo †Institute of Pathology, Medical Faculty, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
    In the early stages of cutaneous malignant melanoma (MM), it is extremely difficult to predict adequately the risk from hematogenic and lymphatic metastasis. We investigate whether the immunohistochemical expression of Ki-67 and estrogen receptor beta (ERβ) in cells of MM could predict the status of regional lymph nodes. A total of 55 tissue samples of primary cutaneous melanomas with known status of regional lymph nodes were retrospectively evaluated for Ki-67 and ERβ expression by quantitative immunohistochemistry and then correlated with the status of regional lymph nodes and relevant clinicopathologic parameters. Read More

    Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
    Cancer Invest 2017 May 26:1-13. Epub 2017 May 26.
    c First Department of Internal Medicine, School of Medicine , National and Kapodistrian University of Athens, Laiko General Hospital , Athens , Greece.
    Anti-CTL4-A therapy is associated with development of colitis. We characterized ipilimumab-associated colitis in nine melanoma patients (6 male, mean age: 55.3-yrs). Read More

    Inhibition of melanoma metastasis by dual-peptide PLGA NPS.
    Biopolymers 2017 May 25. Epub 2017 May 25.
    Institute of Science and Technology, Federal University of São Paulo, São José dos Campos, SP, Brazil.
    Despite the positive results observed in vitro and in vivo, clinical trials with bioactive peptides are generally hampered by their fast degradation in the biological system. Two bioactive peptides, P20 (CSSRTMHHC) and the combined peptide C (CVNHPAFACGYGHTMYYHHYQHHL) have been identified as anticancer therapeutics. Combined peptide C consists of peptide C (CVNHPAFAC), a tumor-homing peptide, conjugated to the antiangiogenic peptide HTMYYHHYQHHL with a GYG. Read More

    An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.
    Angew Chem Int Ed Engl 2017 May 26. Epub 2017 May 26.
    Institut für Analytische Chemie, Universität Wien, Währinger Strasse 38, 1090, Wien, Austria.
    Organometallic metal(arene) anticancer agents require ligand exchange for their anticancer activity and this is generally believed to confer low selectivity for potential cellular targets. However, using an integrated proteomics-based target-response profiling approach as a potent hypothesis-generating procedure, we found an unexpected target selectivity of a ruthenium(arene) pyridinecarbothioamide (plecstatin) for plectin, a scaffold protein and cytolinker, which was validated in a plectin knock-out model in vitro. Plectin targeting shows potential as a strategy to inhibit tumor invasiveness as shown in cultured tumor spheroids while oral administration of plecstatin-1 to mice reduces tumor growth more efficiently in the invasive B16 melanoma than in the CT26 colon tumor model. Read More

    Pediatric Predispositional Genetic Risk Communication: Potential Utility for Prevention and Control of Melanoma Risk as an Exemplar.
    J Genet Couns 2017 May 25. Epub 2017 May 25.
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, USA.
    Predispositional genetic testing among minor children is intensely debated due to the potential benefits and harms of providing this type of genetic information to children and their families. Existing guidelines on pediatric genetic testing state that predispositional testing could be appropriate for minors if preventive services exist that mitigate children's risk for or severity of the health condition in question. We use the example of hereditary melanoma to illustrate the rationale for and potential application of genetic risk communication for an adult-onset cancer to a pediatric population where childhood behaviors may reduce risk of disease later in life. Read More

    Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia.
    Ann Surg Oncol 2017 May 25. Epub 2017 May 25.
    Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
    Background: Standardization of the clinical management of melanoma through the formulation of national guidelines, based on interpretation of the existing evidence and consensus expert opinion, seeks to improve quality of care; however, adherence to national guidelines has not been well studied.

    Methods: A population-based, cross-sectional study of the clinical management of all patients with newly notified primary melanomas in the state of New South Wales, Australia, during 2006/2007 was conducted using cancer registry identification and questionnaires completed by treating physicians.

    Results: Surgical margin guidelines were adhered to in 35% of cases; 45% were over treated and 21% were undertreated. Read More

    Challenges in the delivery of therapies to melanoma brain metastases.
    Curr Pharmacol Rep 2016 Dec 9;2(6):309-325. Epub 2016 Nov 9.
    Brain Barriers Research Center, Department of Pharmaceutics, University of Minnesota, Minneapolis, Minnesota, USA.
    Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. Recent approval of several molecularly-targeted agents and biologics has brought hope to patients with this previously untreatable disease. However, patients with symptomatic melanoma brain metastases have often been excluded from pivotal clinical trials. Read More

    In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade.
    Exp Hematol Oncol 2017 24;6:15. Epub 2017 May 24.
    Hollings Cancer Center, Department of Microbiology and Immunology, Medical University of South Carolina, 173 Ashley Ave, Charleston, SC 29425 USA.
    Blockade of the programmed cell death protein 1 (PD1) pathway is clinically effective against human cancers. Although multiple types of malignancies have been shown to respond to PD1 agents, only a small percentage of patients typically benefit from this treatment. In addition, PD1 therapy often causes serious immune-related adverse events. Read More

    Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.
    Mol Cell Proteomics 2017 May 25. Epub 2017 May 25.
    Biochemistry, Vanderbilt University School of Medicine, United States of America
    Quantitative assessment of key proteins that control the tumor-immune interface is one of the most formidable analytical challenges in immunotherapeutics. We developed a targeted mass spectrometry (MS) platform to quantify programmed cell death-1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and programmed cell death 1 ligand 2 (PD-L2) at fmol/microgram protein levels in formalin fixed, paraffin-embedded sections from 22 human melanomas. PD-L1 abundance ranged 50-fold, from approximately 0. Read More

    Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition.
    J Biol Chem 2017 May 25. Epub 2017 May 25.
    Icahn School of Medicine at Mount Sinai, United States;
    The mitochondrial network is a major site of ATP production through the coupled integration of the electron transport chain (ETC) with oxidative phosphorylation. In melanoma, arising from the Val600Glu mutation in the kinase v-RAF murine sarcoma viral oncogene homolog B (BRAFV600E), oncogenic signaling enhances glucose-dependent metabolism, while reducing mitochondrial ATP production. Likewise, when BRAFV600E is pharmacologically inhibited by targeted therapies (e. Read More

    Succinamide derivatives of melampomagnolide B and their anti-cancer activities.
    Bioorg Med Chem 2017 May 8. Epub 2017 May 8.
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Electronic address:
    A series of succinamide derivatives of melampomagnolide B have been synthesized by coupling MMB monosuccinate (2) with various heterocyclic amines to afford compounds 3a-3l. MMB monosuccinate was also reacted with terminal diaminoalkanes to afford dimeric succinamido analogs of MMB (4a-4h). These succinamide analogs of MMB were evaluated for their anti-cancer activity against a panel of sixty human cancer cell lines. Read More

    A randomized, placebo-controlled trial of patient education for acute low back pain (PREVENT Trial): statistical analysis plan.
    Braz J Phys Ther 2017 Apr 14. Epub 2017 Apr 14.
    Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia; Neuroscience Research Australia, Sydney, New South Wales, Australia.
    Background: Statistical analysis plans increase the transparency of decisions made in the analysis of clinical trial results. The purpose of this paper is to detail the planned analyses for the PREVENT trial, a randomized, placebo-controlled trial of patient education for acute low back pain.

    Results: We report the pre-specified principles, methods, and procedures to be adhered to in the main analysis of the PREVENT trial data. Read More

    The feasibility of contrast enhanced ultrasonography (CEUS) in the diagnosis of non-cardiac thoracic disorders of dogs and cats.
    BMC Vet Res 2017 May 25;13(1):141. Epub 2017 May 25.
    Department of Veterinary Medical Sciences, Alma Mater Studiorum - University of Bologna, Via Tolara di Sopra 50, I-40064, Ozzano Emilia, Bologna, Italy.
    Background: This study describes the feasibility of Contrast Enhanced Ultrasonography (CEUS) in the diagnostic work-up of non-cardiac thoracic disorders of small animals. The second aim is to assess the usefulness of CEUS as a direct guide for sample procedures.

    Results: Forty animals, 28 dogs and 12 cats, were included in the study. Read More

    CVE: an R package for interactive variant prioritisation in precision oncology.
    BMC Med Genomics 2017 May 25;10(1):37. Epub 2017 May 25.
    Cancer Research UK Cambridge Centre, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, UK.
    Background: An increasing number of precision oncology programmes are being launched world-wide. To support this development, we present the Cancer Variant Explorer (CVE), an R package with an interactive Shiny web browser interface.

    Results: Leveraging Oncotator and the Drug Gene Interaction Database, CVE offers exploration of variants within single or multiple tumour exomes to identify drivers, resistance mechanisms and to assess druggability. Read More

    (99m) Tc-labeled NGR-Chlorambucil Conjugate, (99m) Tc-HYNIC-CLB-c(NGR) for Targeted Chemotherapy and Molecular Imaging.
    J Labelled Comp Radiopharm 2017 May 25. Epub 2017 May 25.
    Radiopharmaceuticals Division.
    Targeted delivery of chemotherapeutic drug at the tumor site enhances the efficacy with minimum systemic exposure. Towards this drugs conjugated with peptides having affinity towards a particular molecular target are recognized as affective agents for targeted chemotherapy. Thus in the present study tumor homing NGR peptide ligand was conjugated to DNA alkylating nitrogen mustard, chlorambucil (CLB). Read More

    Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
    PLoS One 2017 17;12(5):e0177830. Epub 2017 May 17.
    Department of Biochemistry and Molecular Biology, College of Medicine, Medical University of South Carolina, Charleston, SC, United States of America.
    ILEI (FAM3C) is a secreted factor that contributes to the epithelial-to-mesenchymal transition (EMT), a cell biological process that confers metastatic properties to a tumor cell. Initially, we found that ILEI mRNA is highly expressed in melanoma metastases but not in primary tumors, suggesting that ILEI contributes to the malignant properties of melanoma. While melanoma is not an epithelial cell-derived tumor and does not undergo a traditional EMT, melanoma undergoes a similar process known as phenotype switching in which high (micropthalmia-related transcription factor) MITF expressing (MITF-high) proliferative cells switch to a low expressing (MITF-low) invasive state. Read More

    Ubiquitination in melanoma pathogenesis and treatment.
    Cancer Med 2017 May 23. Epub 2017 May 23.
    Department of Dermatology, Xijing hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
    Melanoma is one of the most aggressive skin cancers with fiercely increasing incidence and mortality. Since the progressive understanding of the mutational landscape and immunologic pathogenic factors in melanoma, the targeted therapy and immunotherapy have been recently established and gained unprecedented improvements for melanoma treatment. However, the prognosis of melanoma patients remains unoptimistic mainly due to the resistance and nonresponse to current available drugs. Read More

    The first transepidermal transplantation of non-cultured epidermal suspension using a dermarolling system in vitiligo: A sequential histological and clinical study.
    Pigment Cell Melanoma Res 2017 May 19. Epub 2017 May 19.
    Vitiligo Melasma Research Association, 2, Corniche de la Meyjande, Lacanau, 33680, France.
    The current methods for melanocyte delivery to depigmented skin are invasive and often require sophisticated approaches. Here we describe a promising simple and minimally invasive technique based on the dermarolling system. The technique involves preparation of a keratinocyte/melanocyte suspension prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermaroller equipped with 0. Read More

    Ultraviolet radiation accelerates NRas-mutant melanomagenesis: a cooperative effect blocked by sunscreen.
    Pigment Cell Melanoma Res 2017 May 24. Epub 2017 May 24.
    Department of Cancer Biology and Genetics, The Ohio State University, Biomedical Research Tower, 460 W. 12th Avenue, Columbus, OH 43210.
    To mitigate melanoma risk, sunscreen use is widely advocated; yet, the ability of sunscreens to prevent melanoma remains controversial. Here, we test the tenet that sunscreens limit melanoma risk by blocking ultraviolet radiation (UV)-induced DNA damage using murine models that recapitulate the genetics and spontaneous evolution of human melanoma. We find that a single, non-erythematous dose of UV dramatically accelerates melanoma onset and increases tumor multiplicity in mice carrying an endogenous, melanocyte-specific NRas(61R) allele. Read More

    Human Hairless Protein Roles in Skin/Hair and Emerging Connections to Brain and Other Cancers.
    J Cell Biochem 2017 May 23. Epub 2017 May 23.
    Department of Basic Medical Sciences, College of Medicine-Phoenix, University of Arizona. Phoenix, AZ 85004-2153.
    The mammalian hairless protein (HR) is a 130 kDa nuclear transcription factor that is essential for proper skin and hair follicle function. Previous studies have focused on the role of HR in skin maintenance and hair cycling. However, hairless gene (HR) is also expressed in brain and other tissues, where its role remains poorly understood. Read More

    Design, Synthesis, and Biological Evaluation of Coumarin-Triazole Hybrid Molecules as Potential Antitumor and Pancreatic Lipase Agents.
    Arch Pharm (Weinheim) 2017 May 22. Epub 2017 May 22.
    Faculty of Arts and Sciences, Department of Biology, Recep Tayyip Erdogan University, Rize, Turkey.
    The design, synthesis, and investigation of antitumor and anti-lipase activities of some coumarin-triazole hybrid molecules are reported. The synthesis of these hybrid molecules was performed under microwave irradiation and conventional heating procedures. The newly synthesized hybrid molecules were investigated as inhibitors against four tumor cell lines (BT20 human breast carcinoma, SK-Mel 128 melanoma, DU-145 prostate carcinoma, and A549 lung carcinoma) and porcine pancreatic lipase (PPL). Read More

    Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases.
    J Eur Acad Dermatol Venereol 2017 May 22. Epub 2017 May 22.
    Department of Dermatology, University Hospital of Saint Etienne, France.
    Background: Mucosal melanomas are rare and highly aggressive tumors. Few studies evaluated mucosal melanomas of locations other than the head and neck region, and other than those of the Asian population.

    Objectives: The objective of this study was to analyze the clinical and histological features, as well as the mutational status of c-kit and b-raf gene of mucosal melanoma in any localization in a French series. Read More

    Interaction of molecular alterations with immune response in melanoma.
    Cancer 2017 Jun;123(S11):2130-2142
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. Read More

    Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Cancer 2017 Jun;123(S11):2143-2153
    Department of Dermatology and Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
    Immunotherapy for metastatic melanoma has a decades-long history, and the relatively recent use of checkpoint inhibitors has revolutionized treatment. Durable and sometimes complete remission of metastatic melanoma is now achievable in some patients who receive checkpoint-blocking therapy. However, it is unclear why some patients fare better than others. Read More

    Adoptive T cell therapy: An overview of obstacles and opportunities.
    Cancer 2017 Jun;123(S11):2154-2162
    The Ella Lemelbaum Institute of Immuno-oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel.
    The therapeutic potential of adoptive cell therapy (ACT) in cancer patients was first acknowledged 3 decades ago, but it was an esoteric approach at the time. In recent years, technological advancements have transformed ACT into a viable therapeutic option that can be curative in some patients. In fact, current ACT response rates are 80% to 90% for hematological malignancies and 30% for metastatic melanoma refractory to multiple lines of therapy. Read More

    Molecular insights into melanoma brain metastases.
    Cancer 2017 Jun;123(S11):2163-2175
    Department of Dermatology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.
    Substantial proportions of patients with metastatic melanoma develop brain metastases during the course of their disease, often resulting in significant morbidity and death. Despite recent advances with BRAF/MEK and immune-checkpoint inhibitors in the treatment of patients who have melanoma with extracerebral metastases, patients who have melanoma brain metastases still have poor overall survival, highlighting the need for further therapy options. A deeper understanding of the molecular pathways involved in the development of melanoma brain metastases is required to develop more brain-specific therapies. Read More

    Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer 2017 Jun;123(S11):2118-2129
    Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
    The identification of driver mutations in melanoma has changed the field of cancer treatment. BRAF and NRAS mutations are predominant in melanoma and lead to overactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways. Selective inhibitors targeting key effectors of the MAPK pathway have revolutionized the treatment of patients with advanced metastatic BRAF-mutant melanoma. Read More

    Genetically engineered mouse models of melanoma.
    Cancer 2017 Jun;123(S11):2089-2103
    Fels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
    Melanoma is a complex disease that exhibits highly heterogeneous etiological, histopathological, and genetic features, as well as therapeutic responses. Genetically engineered mouse (GEM) models provide powerful tools to unravel the molecular mechanisms critical for melanoma development and drug resistance. Here, we expound briefly the basis of the mouse modeling design, the available technology for genetic engineering, and the aspects influencing the use of GEMs to model melanoma. Read More

    Somatic driver mutations in melanoma.
    Cancer 2017 Jun;123(S11):2104-2117
    Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
    Melanoma has one of the highest somatic mutational burdens among solid malignancies. Although the rapid progress in genomic research has contributed immensely to our understanding of the pathogenesis of melanoma, the clinical significance of the vast array of genomic alterations discovered by next-generation sequencing is far from being fully characterized. Most mutations prevalent in melanoma are simply neutral "passengers," which accompany functionally significant "drivers" under transforming conditions. Read More

    Reflectance confocal microscopy analysis of equivocal melanocytic lesions with severe regression.
    Skin Res Technol 2017 May 21. Epub 2017 May 21.
    Department of Dermatologic Clinic, San Gallicano Dermatological Institute - IRCCS, Rome, Italy.
    Background: The differential diagnosis between regressing nevi and melanoma might be challenging; regressing areas can represent a confounding factor for the diagnosis and the histology still remain mandatory to rule out melanoma. Reflectance confocal microscopy may add valuable information by revealing features suggestive of the nature of the melanocytic proliferation.

    Objective: To assess the impact of confocal microscopy in the management of regressive melanocytic lesions. Read More

    Intraepidermal Merkel cell carcinoma: a case series of a rare entity with clinical follow-up.
    J Cutan Pathol 2017 May 23. Epub 2017 May 23.
    Department of Pathology, Dermatopathology Section, The University of Texas MD, Anderson Cancer Center, Houston, TX, USA.
    Background: Merkel cell carcinoma (MCC) is a rare but aggressive cutaneous carcinoma. MCC involves typically dermis and although epidermotropism has been reported, MCC strictly intraepidermal or in situ (MCCIS) is exceedingly rare. Most of the cases of MCCIS described so far have associated other lesions, such as squamous or basal cell carcinoma, actinic keratosis, etc. Read More

    The prognostic importance of scalp location in primary head and neck melanoma.
    J Surg Oncol 2017 May 22. Epub 2017 May 22.
    John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California.
    Background And Objectives: For patients with cutaneous melanoma, primary tumors located in the head and neck is associated with poor outcomes. The reason for this difference and whether it is applicable to all locations within the head and neck remains unclear. We hypothesized that scalp melanoma is uniquely distinguished from other anatomic sites and is independently responsible for the poor prognosis of head and neck melanoma. Read More

    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol 2017 May 25. Epub 2017 May 25.
    Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
    With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for SPMs among 23 879 patients who survived at least 1 year after a first primary DLBCL diagnosed during 1989-2012, compared to the general population in California. Cumulative incidence (CMI) of SPMs, accounting for the competing risk of death, also was calculated. Read More

    Knowledge deficit, attitude and behavior scales association to objective measures of sun exposure and sunburn in a Danish population based sample.
    PLoS One 2017 25;12(5):e0178190. Epub 2017 May 25.
    Department of Prevention and Information, Danish Cancer Society, Strandboulevarden 49, Copenhagen Ø, Denmark.
    The objective of this study was to develop new scales measuring knowledge and attitude about UVR and sun related behavior, and to examine their association to sun related behavior objectively measured by personal dosimetry. During May-August 2013, 664 Danes wore a personal electronic UV-dosimeter for one week that measured their UVR exposure. Afterwards, they answered a questionnaire on sun-related items. Read More

    Functional interaction between co-expressed MAGE-A proteins.
    PLoS One 2017 24;12(5):e0178370. Epub 2017 May 24.
    Lab. Oncología Molecular, Departamento de Química Biológica and IQUIBICEN-UBA/CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.
    MAGE-A (Melanoma Antigen Genes-A) are tumor-associated proteins with expression in a broad spectrum of human tumors and normal germ cells. MAGE-A gene expression and function are being increasingly investigated to better understand the mechanisms by which MAGE proteins collaborate in tumorigenesis and whether their detection could be useful for disease prognosis purposes. Alterations in epigenetic mechanisms involved in MAGE gene silencing cause their frequent co-expression in tumor cells. Read More

    Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.
    PLoS One 2017 19;12(5):e0177736. Epub 2017 May 19.
    Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands.
    Background: Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly humanized or fully human immunoglobulin G1 (IgG1). These antibodies bind with high affinity to the target antigen and are efficient in activating the immune system via IgG Fc receptors and/or complement. In addition to IgG1, three more isotypes are present in humans, of which IgG3 has been found to be superior compared to human IgG1 in inducing antibody dependent cell cytotoxicity (ADCC), phagocytosis or activation of complement in some models. Read More

    An incomplete picture: challenges of partial biopsies in large diameter atypical melanocytic lesions.
    Dermatol Online J 2017 Apr 15;23(4). Epub 2017 Apr 15.
    Pigmented Lesion Clinic; Department of Dermatology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
    Large diameter atypical pigmented lesions (LDAPL) can be challenging to diagnose accurately using partial biopsies because of pathologic heterogeneity, while at the same time large excisions of these lesions confer significant morbidity to patients. Consequently, clinicians are often challenged by the management of these lesions. In this case, we describe an elderly patient with a history of multiple basal cell carcinomas, prior melanomas, and a family history of melanoma who presented with an irregularly pigmented brown and dark brown patch on his upper back. Read More

    1 OF 2265